BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17187494)

  • 1. Schizophrenia: more evidence for less glutamate.
    Morrison PD; Pilowsky LS
    Expert Rev Neurother; 2007 Jan; 7(1):29-31. PubMed ID: 17187494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.
    Hahn CG; Wang HY; Cho DS; Talbot K; Gur RE; Berrettini WH; Bakshi K; Kamins J; Borgmann-Winter KE; Siegel SJ; Gallop RJ; Arnold SE
    Nat Med; 2006 Jul; 12(7):824-8. PubMed ID: 16767099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.
    Bennett M
    Aust N Z J Psychiatry; 2009 Aug; 43(8):711-21. PubMed ID: 19629792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life.
    du Bois TM; Newell KA; Huang XF
    Eur Neuropsychopharmacol; 2012 May; 22(5):356-63. PubMed ID: 21962913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice.
    Newell KA; Karl T; Huang XF
    Neuroscience; 2013 Sep; 248():670-80. PubMed ID: 23811072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.
    Pan B; Huang XF; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):924-30. PubMed ID: 21513767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.
    Geddes AE; Huang XF; Newell KA
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):896-904. PubMed ID: 21371516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors.
    Pitcher GM; Kalia LV; Ng D; Goodfellow NM; Yee KT; Lambe EK; Salter MW
    Nat Med; 2011 Apr; 17(4):470-8. PubMed ID: 21441918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuregulin 1/ErbB4 enhances synchronized oscillations of prefrontal cortex neurons via inhibitory synapses.
    Hou XJ; Ni KM; Yang JM; Li XM
    Neuroscience; 2014 Mar; 261():107-17. PubMed ID: 24374327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia.
    Errico F; Napolitano F; Squillace M; Vitucci D; Blasi G; de Bartolomeis A; Bertolino A; D'Aniello A; Usiello A
    J Psychiatr Res; 2013 Oct; 47(10):1432-7. PubMed ID: 23835041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRG1 and synaptic function in the CNS.
    Fischbach GD
    Neuron; 2007 May; 54(4):495-7. PubMed ID: 17521560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prefrontal NMDA receptor antagonism reduces impairments in pre-attentive information processing.
    Klamer D; Svensson L; Fejgin K; Pålsson E
    Eur Neuropsychopharmacol; 2011 Mar; 21(3):248-53. PubMed ID: 21111580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
    Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuregulin 1 Type I Overexpression Is Associated with Reduced NMDA Receptor-Mediated Synaptic Signaling in Hippocampal Interneurons Expressing PV or CCK.
    Kotzadimitriou D; Nissen W; Paizs M; Newton K; Harrison PJ; Paulsen O; Lamsa K
    eNeuro; 2018; 5(2):. PubMed ID: 29740596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin-1 enhances depolarization-induced GABA release.
    Woo RS; Li XM; Tao Y; Carpenter-Hyland E; Huang YZ; Weber J; Neiswender H; Dong XP; Wu J; Gassmann M; Lai C; Xiong WC; Gao TM; Mei L
    Neuron; 2007 May; 54(4):599-610. PubMed ID: 17521572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons.
    Allison JG; Das PM; Ma J; Inglis FM; Jones FE
    Neurosci Res; 2011 Jun; 70(2):155-63. PubMed ID: 21352860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model of neuregulin control of NMDA receptors on synaptic spines.
    Bennett MR; Farnell L; Gibson WG
    Bull Math Biol; 2012 Mar; 74(3):717-35. PubMed ID: 22147103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.